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Abstract
HPV infrequently persists and progresses to cervical cancer. We examined host genetic factors hypothesized to play a role in
determining which subset of individuals infected with oncogenic human papillomavirus (HPV) have persistent infection and
further develop cervical pre-cancer/cancer compared to the majority of infected individuals who will clear infection. We
evaluated 7140 tag single nucleotide polymorphisms (SNPs) from 305 candidate genes hypothesized to be involved in DNA
repair, viral infection and cell entry in 416 cervical intraepithelial neoplasia 3 (CIN3)/cancer cases, 356 HPV persistent women
(median: 25 months), and 425 random controls (RC) from the 10,049 women Guanacaste Costa Rica Natural History study.
We used logistic regression to compute odds ratios and p-trend for CIN3/cancer and HPV persistence in relation to SNP
genotypes and haplotypes (adjusted for age). We obtained pathway and gene-level summary of associations by computing
the adaptive combination of p-values. Genes/regions statistically significantly associated with CIN3/cancer included the viral
infection and cell entry genes 29,59 oligoadenylate synthetase gene 3 (OAS3), sulfatase 1 (SULF1), and interferon gamma
(IFNG); the DNA repair genes deoxyuridine triphosphate (DUT), dosage suppressor of mck 1 homolog (DMC1), and general
transcription factor IIH, polypeptide 3 (GTF2H4); and the EVER1 and EVER2 genes (p,0.01). From each region, the single
most significant SNPs associated with CIN3/cancer were OAS3 rs12302655, SULF1 rs4737999, IFNG rs11177074, DUT
rs3784621, DMC1 rs5757133, GTF2H4 rs2894054, EVER1/EVER2 rs9893818 (p-trends#0.001). SNPs for OAS3, SULF1, DUT, and
GTF2H4 were associated with HPV persistence whereas IFNG and EVER1/EVER2 SNPs were associated with progression to
CIN3/cancer. We note that the associations observed were less than two-fold. We identified variations DNA repair and viral
binding and cell entry genes associated with CIN3/cancer. Our results require replication but suggest that different genes
may be responsible for modulating risk in the two critical transition steps important for cervical carcinogenesis: HPV
persistence and disease progression.
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Introduction
Persistent infection with one of approximately 15 types of
human papillomavirus (HPV) is necessary for the development of
cervical cancer and its immediate precursor, cervical intraepithe-
lial neoplasia grade 3 (CIN3). However, HPV infection is not a
sufficient cause of cervical cancer/CIN3 and HPV cofactors have
been identified, including oral contraceptive use and smoking [1].
Familial aggregation studies and evaluation of inherited genetic
variations further suggest that host genetic factors may also
contribute to cervical cancer pathogenesis [2]. A number of studies
have evaluated and implicated a role for human leukocyte antigens
(HLA) [3,4]. We previously reported the association between
common variants in genes influencing DNA damage, notably,
FANCA, associated with both HPV persistence and progression to
CIN3/cancer. We also reported a variant in the innate immunity
gene IRF3 associated with HPV persistence [5]. Here, we expand
our evaluation of host genetic variations in DNA repair, viral
infection and cell entry genes and risk for HPV persistence and
cervical precancer/cancer.
We evaluated data on 7,140 candidate single nucleotide
polymorphisms (SNP) in 305 candidate genes/regions (161 viral
infection and cell entry and 144 DNA repair genes). All known DNA
repair genes were included [6] and viral infection and cell entry genes
were selected based on biological evidence of hypothesized
association with cervical cancer, HPV, or other infections. All genes
and their selected variants were evaluated for risk of HPV persistence
and progression to CIN3/cancer within the population-based
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Table S1). A unique aspect of our effort is the ability to separately
evaluate genetic factors associated with the two known and critical
transition states in the natural history of cervical cancer – (i) viral
persistence and (ii) progression to pre-cancer/cancer.
Results
Pathway-Based Associations
We found the DNA repair pathway as a whole statistically
significantly associated with CIN3/cancer (p=0.0197) and with
HPV persistence (p=0.0472) but not progression (p=0.7451)
(Table 1). These associations appeared driven by genes involved in
editing/processing nucleases, modulation of nucleotide pools, and
nucleotide excision repair. The family of Fanconi anemia genes
was also significantly associated with HPV persistence (p=0.0326).
Gene/Region-Based Associations
Table 2 shows results for 9 genes/regions associated with CIN3/
cancer compared to random controls at p,0.01, ordered by their
statistical significance. Six of the genes wereconsidered notable with
a FDR#0.2, includingthe DNArepairgenes - GTF2H4,DUT,a n d
DMC1 – and the viral infection and cell entry related genes - OAS3,
SULF1,a n dIFNG. The association for GTF2H4 and SULF1 were
also associated with HPV persistence (p=0.005). Three regions
were statistically significantly associated with progression to CIN3/
cancer at p,0.05: TMC6 (EVER1), TMC8 (EVER2),a n d
FLJ35220. All gene-based results are shown in Table S2.
SNP-Based Associations
Consistent with our gene/region-based analyses, we found
evidence of an altered risk (approximately 2-fold) for CIN3/cancer
for one or more SNPs in eight of the nine genes/regions with p-
trends #0.001 (Table 3, SNPs ordered alphabetically by gene
name). Of the four genes associated with HPV persistence, SNPs
in DUT (rs3784621), GTF2H4 (rs2894054, rs6926723), OAS3
(rs12302655), and SULF1 (rs4737999, rs4284050, rs10108002)
had significant p-trend,0.05. Of the genes/regions associated
with progression to CIN3/cancer, SNPs in IFNG (rs11177074) and
between EVER2/TMC8 and EVER1/TMC6 (rs9893818) were
statistically significant at p,0.05. Odds ratios and 95% confidence
intervals for these SNPs are shown in Table S3 (all data for all
SNPs are shown in Table S4). We note that other SNPs associated
with CIN3/cancer included those in the OAS1, OAS2, and POLN
genes (Table 3). As for OAS3, the associations with OAS1 and OAS2
were significant for HPV persistence whereas POLN was associated
with disease progression.
Haplotype Associations
Results from haplotype-based analyses (defined by blocks of
linkage disequilibrium) were generally consistent with the gene/
region- and SNP-based findings. Haplotypes statistically signifi-
Table 1. Pathway-based tests for significance among DNA repair genes for associations with (i) cervical precancer/cancer, (ii)
progression to cervical precancer/cancer, and (iii) HPV persistence.
DNA Repair Pathway Genes
#
genes
#
SNPs
(i) CIN3/CA
vs RC
(ii) CIN3/CA vs
HPV persisters
(iii) HPV
persisters
vs RC
All genes 138 2985 0.0197 0.7451 0.0473
Base excision repair UNG, SMUG1, MBD4, TDG, OGG1, MUTYH, NTHL1, MPG, NEIL1, NEIL2,
APEX1, APEX2, LIG3, XRCC1, PNKP, PARP1, PARP2
17 363 0.1961 0.6703 0.1609
Chromatin Structure H2AFX, CHAF1A 2 27 0.6365 0.0912 0.3588
DNA polymerases POLB, POLG, POLD1, POLE, PCNA, REV3L, MAD2L2, REV1L, POLH, POLI,
POLQ, POLK, POLL, POLM, POLN
14 289 0.2588 0.7481 0.6309
Direct reversal of damage MGMT, ALKBH3 2 105 0.9515 0.9996 0.9975
Editing/processing nucleases FEN1, TREX1, TREX2, EXO1, SPO11, FLJ35220 69 50.0096 0.1961 0.3546
Genes defective in diseases
associated with sensitivity to
DNA damaging agents
BLM, WRN, RECQL4, ATM 4 101 0.2465 0.2051 0.0732
Fanconi anemia FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL,
FANCM, FANCN (PALB2), C19ORF40
10 222 0.6062 0.2230 0.0326
Homologous recombination RAD51, RAD51C, RAD51L3, DMC1, XRCC2, XRCC3, RAD52, RAD54L,
RAD54B, BRCA1, BRCA2, SHFM1, RAD50, MRE11A, MUS81, EME1, EME2
17 364 0.1185 0.7500 0.2318
Mismatch excision repair MSH2, MSH3, MSH6, MSH4, MSH5, PMS1, MLH1, PMS2, MLH3, PMS2L3 10 254 0.7061 0.1263 0.4253
Modulation of nucleotide pools NUDT1, DUT, RRM2B. 35 10.0181 0.6242 0.2219
Non-homologous end-joining XRCC5, PRKDC, LIG4, XRCC4, DCLRE1C 5 200 0.4068 0.7096 0.6697
Nucleotide excision repair XPC, RAD23B, CETN2, RAD23A, XPA, RPA1, RPA2, RAP3, ERCC2, ERCC3,
GTF2H1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, CDK7, CCNH, MNAT1,
ERCC5, ERCC1, ERCC4, LIG1, ERCC6, XAB2, DDB1, DDB2, MMS19L
26 607 0.0438 0.7382 0.2982
Other genes with suspected
DNA repair function
CDLRE1A, CDLRE1B, RPA4, APTX, NEIL3, RECQL, RECQL5, HEL308, RDM1 9 139 0.1382 0.3793 0.2542
Other conserved DNA damage
response genes
ATR, RAD1, RAD9A, HUS1, RAD17, CHEK1, CHEK2, TP53, TREX1, PER1 9 127 0.8380 0.8285 0.4497
Rad6 pathway UBE2A, UBE2B, RAD18, UBE2V2, UBE2N 5 54 0.6558 0.9324 0.8099
P values are based on the adaptive rank truncated product method.
doi:10.1371/journal.pone.0008667.t001
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SNP-based analysis (as shown in Table S5 for DUT, GTF2H4 and
SULF1 where haplotype blocks could be constructed). No new
regions of interest were identified in haplotype analysis using the
sliding window approach of 3 SNPs (data not shown).
Discussion
In this population-based study, we found nine genes/regions
associated with CIN3/cancer, 6 of which remained significant at
aF D R #0.2 – three DNA repair genes (GTF2H4, DUT, and
DMC1) and three viral infection and cell entry related genes
(OAS3, SULF1, and IFNG). A unique aspect of our study is the
ability to separately evaluate associations with the two important
transition steps in the natural history of cervical cancer – viral
persistence and progression to precancer/cancer. Of the regions/
genes found to be important, the association was primarily with
HPV persistence for GTF2H4 and SULF1. IFNG and the
epidermodysplasia verruciformis (EV)-associated genes (TMC6-
EVER1 and TMC8-EVER2) were primarily associated with
progression to CIN3/cancer. All top genes derived from the
gene/region- and SNP-based analyses are annotated and briefly
described in Table 4.
Results for our DNA repair pathway-based analyses were
consistent with our individual SNP-based results. Specifically, we
found that genes within nucleotide excision repair (which includes
GTF2H4) and modulation of nucleotide pools (which includes
DUT) to be associated with HPV persistence. The DNA repair
family of editing/processing of nucleases was associated with
progression to CIN3/cancer and though several genes were
Table 2. Significance levels (p values) for (i) cervical precancer/cancer, (ii) progression to cervical precancer/cancer, and (iii) HPV
persistence, among gene regions with p,0.01 for an association with cervical precancer/cancer.
Gene Chromosome # SNPs (i) CIN3/CA (ii) CIN3/CA (iii) HPV persistence+
vs. RC vs. HPV persistence vs. RC
OAS3 12q24.2 36 0.0013* 0.2537 0.1354
GTF2H4 6p21.3 15 0.0018* 0.5355 0.0054
SULF1 8q13.3 77 0.0030* 0.6935 0.0056
DUT 15q15-q21.1 14 0.0038* 0.2399 0.0612
IFNG 12q14 10 0.0038* 0.0511 0.9136
DMC1 17q25.1 14 0.0038* 0.5865 0.4742
TMC8 (EVER2) 17q25.3 22 0.0081 0.0287 0.8114
TMC6 (EVER1) 17q25.3 26 0.0098 0.0309 0.8457
FLJ35220 17q25.3 18 0.0094 0.0232 0.0864
*FDR p#0.2.
Results for all gene-based tests are shown in Table S2.
doi:10.1371/journal.pone.0008667.t002
Table 3. Significance levels (p values) for (i) cervical precancer/cancer, (ii) progression to cervical precancer/cancer, and (iii) HPV
persistence, among SNPs with p#0.001 for an association with cervical precancer/cancer.
Gene rs # (i) CIN3/CA (ii) CIN3/CA (iii) HPV persistence
vs. RC vs. HPV persistence Vs. RC
DMC1 RS5757133 0.0007 0.1590 0.1114
DUT RS3784621 0.0004* 0.1280 0.0262
GTF2H4 RS2894054 0.0001* 0.8742 0.0002
GTF2H4 RS6926723 0.0004 0.6840 0.0034
IFNG RS11177074 0.0003 0.0095 0.4011
OAS1 RS12307655 0.0005* 0.2790 0.0034
OAS2 RS718802 0.0001 0.1844 0.0057
OAS3 RS12302655 0.00008 0.1909 0.0025
POLN RS17132382 0.0011 0.0103 0.5304
SULF1 RS4737999 0.0001* 0.8918 0.0020
SULF1 RS4284050 0.0007 0.4994 0.0020
SULF1 RS10108002 0.0010 0.5160 0.0181
TMC8,TMC6 RS9893818 0.0003 0.0019 0.8434
*p,0.05 in oncogenic HPV+ restricted analyses.
SNP p values with FDR p,0.2 are denoted with astericks. Complete results for SNP-based results are shown in Supplemental Materials (Table S3 (SNPs listed in Table 2)
and Table S4 (all)).
doi:10.1371/journal.pone.0008667.t003
Host Genes, HPV and Cancer
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association between the Fanconi Anemia family of genes with
HPV persistence is also consistent with our previous analyses that
reported FANCA variants associated with HPV persistence (5).
There have been no reports of polymorphisms in GTF2H4, DUT
or DMC with HPV persistence, cervical cancer, or any other
cancer to date. However, GTF2H4 is located on chromosome
6p21.3 within the HLA region and is thus of note as a number of
studies have investigated HLA Class II and I genes with cervical
cancer and have consistently identified alleles (e.g., HLA-
DRB*1301) associated with cervical cancer [4]. Whether the
observed association between GTF2H4 variants and HPV
persistence is due to its biological function and its capacity as a
DNA repair gene or to potential linkage disequilibrium with HLA
requires further evaluation.
Variants in two genes postulated to play a role in viral and
HPV binding, OAS3 and SULF1, were also associated with HPV
persistence in our population. OAS3 plays a role in resistance to
viral infection via degradation of viral and cellular RNAs and
impairment of viral replication. Specifically, the OAS family of
genes (OAS1, OAS2, OAS3) is induced by interferon. When
enzymatically active OAS are bound to viral RNA, RNase L is
activated, resulting in the degradation of viral RNA [7].
Notably, OAS1 and OAS2 SNPs were also associated with
HPV persistence in our population (Table 3). SULF1 (sulfatase
1) is involved in cell signaling and is a coreceptor for heparin-
binding growth factors and cytokines. Sulfs potentially play a
role in a cellular feed-back mechanism where they edit the
sulfation of multiple heparin sulfate proteoglycans [8]. This is of
particular interest as heparin sulfate proteoglycans are thought
Table 4. Description of top-ranked genes.
Gene (Alias) Chromosome Gene Description* Gene ontology** Additional Comments
Selected
References
DNA repair
DMC1 17q25.1 ?22q13.1 Dosage suppressor of mck1
homolog, meiosis-specific
homologous recombination
Female gamete generation; meiosis;
reciprocal meiotic recombination;
spermatogenesis; ATP binding; DNA
binding
Rad51 homolog, meiosis (6)
DUT 15q15-q21.1 Deoxyuridine triphosphatase DNA replication; nucleobase,
nucleoside, nucleotide and nucleic
acid metabolic process; dUTP
disphosphatase activity
Modulation of nucleotide
pools
(6)
FLJ35220
(ENDOV)
17q25.3 Hypothetical protein FLJ35220 Editing/processing nucleases;
incision 39 of hypoxanthine
and uracil
(6)
GTF2H4 6p21.3 General transcription factor IIH,
polypeptide 4
DNA repair; nucleotide-excision repair,
DNA damage removal; RNA elongation
from RNA polymerase II promoter
Nucleotide excision repair;
core TFIIH subunit p52
(6)
POLN (POL4P) 4p16.2 Polymerase (DNA directed) nu DNA-dependent DNA replication; DNA-
directed DNA polymerase activity
DNA polymerase; DNA
crosslink repair
(6)
HPV binding/immune-related genes
IFNG 12q14 Interferon, gamma Cell cycle arrest; cell motion; signal
tranduction
Cytokine with role in innate/
adaptive immunity against viral/
bacterial infections; role
in tumor control
OMIM
OAS1 12q24.2 29-59-oligoadenylate synthetase 1 Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
Role in resistance to viral
infection via degradation of
viral and cellular RNAs and
impairment of viral replication.
Also implicated in control of cell
growth, differentiation, and
apoptosis.
OMIM
OAS2 12q24.2 29-59-oligoadenylate synthetase 2 Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
Resistance to viral infection
(see OAS1)
OMIM
OAS3 12q24.2 29-59-oligoadenylate synthetase 3 Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
Resistance to viral infection
(see OAS1)
OMIM
SULF1 8q13.3 Sulfatase 1 Heparin sulfate proteoglycan
metabolic process; arylsulfatase
activity
Coreceptor for heparin-binding
growth factors and cytokines;
involved in cell signaling
OMIM
TMC8 (EVER2) 17q25.3 Transmembrane channel-like 8 Epidermodysplasia verruciformis
susceptibility gene
(20)
TMC6 (EVER1) 17q25.3 Transmembrane channel-like 6 Epidermodysplasia verruciformis
susceptibility gene
(20)
*As defined in NCBI Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez); **Gene Ontology annotation (http://www.geneontology.org/); OMIM: http://www.ncbi.nlm.
nih.gov/sites/entrez; GeneCards: http://www.genecards.org; (1) Supplement to Wood RD, Mitchell M, Lindahl T Mutation Research 2005 (http://www.cgal.icnet.uk/
DNA_Repair_Genes.html); (2) Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol.
2008;321:59-83.
doi:10.1371/journal.pone.0008667.t004
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with heparin and heparin sulfate have inhibited infection of
some HPV types [9].
Three genes were associated primarily with progression to
CIN3/cancer including IFNG, a cytokine that plays a role in
innate immunity against viral or bacterial infections. It also
induces the OAS family of genes which leads to degradation of
viral RNA. We also report an association between genes in
EVER1/TMC6 and EVER2/TMC8 and a SNP that lies between
the two genes with progression to CIN3/cancer. Mutations in
either EVER1 or EVER2 genes are well-documented in the rare
skin carcinoma, epidermodysplasia verruciformis (EV), which is
characterized by infection with HPV5 [10]. That common
polymorphisms within EVER1 and EVER2 are also associated
with progression to CIN3/cancer may potentially suggest a larger
role, though modest, for EVER1 and EVER2 genes in HPV
susceptibility and subsequent risk for disease.
As described previously [5], study limitations may include
potential survival bias as the supplemental cases identified in
Guanacaste were retrospectively ascertained and DNA was not
obtained for deceased cases. Another limitation is our inability to
evaluate invasive cervical cancer separately. Future studies with
larger numbers of cases will be needed to address whether specific
genes are involved in the transition from in situ to invasive disease.
Although we targeted a priori genes and used a FDR of ,0.2 to
determine which genes were notable, we cannot exclude the
possibility of false positives (or false negatives). Importantly,
because our population comprises Costa Ricans and genes were
tagged based on Caucasian and Yoruban populations where data
are available from HapMap, it is plausible that gene coverage in
our Costa Rican population is incomplete. Study strengths include
our population-based study design. This design approximates a
case-cohort design since the proportion of women in the cohort
with CIN3 or cancer is small. Another study strength is our ability
to evaluate genes relevant for HPV persistence and genes relevant
for disease progression. Further, our study had rigorous follow-up,
HPV testing and pathology review for case definitions. Our tag-
SNP approach also allowed for broader coverage of each a priori
gene/region investigation, compared to prior candidate SNP-
based genotyping approaches. Our evaluation of the DNA repair
pathway was near complete based on most recent literature and
allowed for pathway-based analyses. However, our viral binding
and cell entry genes were not amenable to similar analyses. We
acknowledge that our a priori approach sampled a small subset of
genes in the genome and we therefore likely missed other
important associations. Increased power and replication of our
results are required and larger efforts in genome-wide association
studies should shed additional light on genes and regions of
significance for cervical cancer. Our study, however, remains the
only one designed to delineate between associations with HPV
persistence and progression to CIN3/cancer.
In summary, our results require replication but build upon our
previous report of potential host genetic variants relevant for HPV
persistence and those relevant for progression to CIN3/cancer. If
replicated, additional studies to pinpoint the causal SNP(s) and
determine their biological relevance should be pursued. Future
efforts should include further dissection of long-term persistence
that likely leads to progression compared to short-term persistence
that is less likely to progress to CIN3/cancer. The role of host gene
and HPV methylation and their role on causal genes should also
be considered. These data are important for future research in
evaluating the interplay between viral and host genetics in
determining risk of HPV persistence and for progression to
CIN3/cancer.
Methods
Study Population
The present study was nested within a population-based cohort
study of women in Guanacaste, Costa Rica. Details of the cohort
study methods [11,12] and of the sub-population selected for
genetic analyses [5] have been reported elsewhere. Briefly, the
Guanacaste HPV natural history study is a population-based
cohort of 10,049 women recruited over an 18-month period in
1993–94 and followed for seven years. For cohort participants,
cervical cells were available for HPV DNA testing as previously
described [11,12], and buffy coat specimens were available for
host gene polymorphism testing.
Women selected for the genetic study included: (i) all women in
the cohort histologically confirmed with prevalent or incident CIN3
or cancer (n=184); (ii) all women in the cohort with evidence of
HPV persistence, defined as women positive for the same HPV type
at two consecutive visits (n=432) (median length of persistence: 25
months); and (iii) a random selection of controls from the cohort
(n=492) [5]. As described previously [5], we also included 331
supplemental CIN3 and cancer cases from Guanacaste who were
not participants in the natural history study but were independently
diagnosed with CIN3 or cancer during the same period in which
our natural history study was conducted. We note that these
supplemental cases were slightly older because of the larger
proportion of cancers compared to our cohort-based cases where
there was a higher proportion of CIN3. Allele frequencies were
comparable between our cohort and supplemental cases, justifying
the combining of the two groups for genetic analyses (5).
Ethics Statement
The study was approved by both the US NCI and Costa Rica
Institutional Review Boards and all subjects signed informed consent.
Laboratory Methods
DNA extraction. DNA was extracted from buffy coats with
PureGene purification kits/Autopure protocol (Gentra Systems) at
SeraCare (Frederick, MD). For the supplemental cases the DNA
extraction was done at the University of Costa Rica using the same
kit/protocol.
HPV testing. PCR-based HPV DNA testing with L1 MY09/
MY11 consensus primer methods [11,13,14] was conducted on
cervical cells stored in standard transport media (Qiagen,
Germantown, MD) from the natural history study only. Because
cervical cells were not obtained from the supplemental cases, HPV
results are not available for these women. For purposes of HPV-
restricted analyses, supplemental precancer/cancer cases are
presumed to be HPV-positive due to the present knowledge that
oncogenic HPV is an established and necessary risk factor for
cervical precancer/cancer.
Host genotyping. Genotyping of tag SNPs from 305 candidate
genes/regions(Genesand SNPsannotated in TableS1)hypothesized
to be involved in cervical cancer progession or HPV persistence was
conducted at the NCI Core Genotyping Facility (Advanced
Technology Center, Gaithersburg, MD; http://snp500cancer.nci.
nih.gov) [15] using a custom-designed iSelect Infinium assay
(Illumina, www.illumina.com). The Infinium included a total of
27,904 tag SNPs, of which our candidate genes/regions represented
7,765 SNPs. Tag SNPs for the 305 candidate genes werechosen from
the designable set of common SNPs (minor allele frequency
(MAF).5%) genotyped in the Caucasian (CEU) and Yoruban
(YRI) population sample of the HapMap Project (Data Release 20/
Phase II, NCBI Build 36.1 assembly, dbSNPb126) using the software
Tagzilla (http://tagzilla.nci.nih.gov/), which implements a tagging
Host Genes, HPV and Cancer
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Because there is no Costa Rican population in the HapMap Project
for which we could select SNPs, we included tagging for the YRI in
addition to the CEU population to improve our probability of
achieving gene coverage in our population. For each original target
gene, SNPs within the region spanning 20 kb 59 of the start of
transcription (exon 1) to 10 kb 39 of the end of the last exon were
grouped using a binning threshold of r
2.0 . 8t od e f i n eag e n e / r e g i o n .
When there were multiple transcripts available for genes, only the
primary transcript was assessed.
Quality control (QC). Tag SNPs that failed manufacturing
(ordered but did not convert), failed validation (no amplification or
clustering) and assays that had less than 80% completion or 80%
concordance with the 90 Hapmap CEU samples used for
validation were excluded (n=104). SNPs with low completion
rate (,90% of samples) were further excluded (N=138). SNPs
with QC discordance among our 100 QC duplicates and among
HapMap samples ,98% were excluded (n=383). We also
excluded samples with a low completion rate (,90%) (N=7).
Hardy–Weinberg equilibrium was evaluated among controls.
SNPs showing evidence of deviation from Hardy–Weinberg
proportions (n=49, p,0.0001) are denoted in Table S1.
Though our QC data did not suggest any obvious genotyping
error and we present their results, we note caution in
interpretation of these select results. Of the 7,765 a priori SNPs,
7,140 SNPs were included in our present analysis.
Final analytic population. We evaluated a total of 416
women diagnosed with CIN3 or cancer, 356 women with HPV
persistent infection, and 425 random controls for whom validated
genotyping results were obtained.
Statistical Analysis
Pathway- and gene/region-based analyses. We obtained
pathway- and gene/region-based summary of associations using
the adaptive combination of p-values [17,18], which combines
gene-level association evidence through adaptive rank truncated
product method. To account for multiple comparisons, we applied
the false discovery rate (FDR) method of Benjamini and Hochberg
[19]. Pathway-based analyses were conducted for DNA repair
genes; they were not conducted for viral infection and cell entry
genes as only select genes were targeted for evaluation and
together do not fully represent a pathway.
SNP-based associations. We calculated odds ratios (OR)
and 95% confidence intervals(95% CI) for each genotype with each
disease outcome, using the homozygous wild type (WT) genotype as
the referent group. We first compared CIN3/cancer cases to
random controls. We further evaluated whether the statistically
significant associations for CIN3/cancer were consistent for HPV
persistence and/or disease progression with the following respective
comparisons: (i) HPV persisters compared to random controls and
(ii) CIN3/cancer cases compared to HPV persisters.
We conducted both crude and analyses adjusted for age (,30,
30–49, 50+ years). For each outcome, we calculated the Ptrend
based on the three-level ordinal variable (0, 1, and 2) of
homozygote WT, heterozygote, and homozygote variant in a
logistic regression model. For evaluating associations with HPV
persistence, we also conducted analyses where HPV persistence
and controls were restricted to any oncogenic-HPV infection (16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68). All logistic regression
models were unconditional and conducted using SAS version 9.1
(SAS Institute, Cary, NC).
Haplotype analyses. We conducted haplotype analyses using
two methods. First, we evaluated riskof cancer,progression and HPV
persistence associated with haplotypes defined by SNPs within a
sliding window of three loci across a gene (Haplo Stats, version 1.2.1,
haplo.score.slide, http://mayoresearch.mayo.edu/mayo/research/
schaid_lab/software.cfm) on all genes. A global score statistic was
used to summarize the evidence of association of disease with the
haplotypes for each window. Second, we visualized haplotype
structures for genes where p,0.01 for gene/region-based analysis
using Haploview, version 3.11 [20] based on measures of pairwise
linkage disequilibrium between SNPs. For blocks of linkage
disequilibrium, we obtained ORs and 95% CIs for the underlying
haplotypes under the assumption of an additive model (haplo.glm,
minimum haplotype frequency 1%). All haplotype analyses were
adjusted for age.
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